Program overview
Context
Indication: MSI-H/dMMR Solid Tumors
Mechanism: Unknown
Modality: Unknown
Sponsor: BeiGene
Watchlist Signal
Tislelizumab (BGB-A317)
Tislelizumab (BGB-A317) is flagged as watchlist signal because public records show operational burden. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Scores
Risk-signal summary
Registry: 0/5
Timeline: 1/5
Recruitment burden: 2/5
Results availability: 0/5
Program risk: 2/5
Evidence
Public links
https://clinicaltrials.gov/study/NCT03736889
Linked trials
Trial-level signal details
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT03736889 | Low Signal (RECRUITING) | long_recruitment_duration_signal | Low Signal | large_enrollment_target_signal | rare_population_signal |